Close Menu

NEW YORK (GenomeWeb) – Editas Medicine said today that it has priced its previously announced public offering of 4 million shares of common stock at $22.50 per share, giving the transaction a value of $90 million before expenses.

Morgan Stanley and JP Morgan will act as joint book running managers. Cowen and Company is acting as lead manager while JMP Securities is acting as co-manager. Editas has granted the underwriters a 30-day option to purchase an additional 600,000 shares.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.